Korro's KRRO-111 Edits SERPINA1 Up to 96% in Preclinical AATD Data, Filing Set for 1H 2027
KRRO sits 80% above its 52-week low of $5.204.
Summary
Korro reported preclinical KRRO-111 data in alpha-1 antitrypsin deficiency: up to 96% SERPINA1 mRNA editing, M-AAT at up to 93% of circulating AAT, and liver Z-AAT cut 95% at Day 57 in mice. Total AAT reached 172 μM, roughly 6x vehicle, with single-dose effects lasting to at least Day 42 — supporting a redosable subcutaneous profile. The company targets a regulatory submission for KRRO-111 in the first half of 2027, which would open the path to first-in-human testing. This is early-stage and still needs GLP tox and clearance, but it positions KRRO-111 as a dual lung-liver AATD candidate and broadens the pipeline beyond lead asset KRRO-121, which dosed its first ANCHOR cohort earlier this month. The 8-K filed today carries the same disclosure. With $137.9M in cash and runway into 2H 2028 per the Q2 10-Q, funding the tox package is not the constraint; execution on the 1H 2027 filing is.
At the time of this announcement, KRRO was trading at $9.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.8M. The 52-week trading range was $5.20 to $46.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.